Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Xilio Therapeutics ( (XLO) ) just unveiled an update.
On January 21, 2025, Xilio Therapeutics announced initial data from a Phase 2 clinical trial evaluating vilastobart (XTX101) combined with atezolizumab for advanced solid tumors, which will be presented at the 2025 ASCO Gastrointestinal Cancer Symposium. This development marks a significant step in Xilio’s clinical programs, highlighting its potential impact on the oncology landscape and providing insights into their collaboration with Roche and strategic goals in advancing cancer treatment options.
More about Xilio Therapeutics
Xilio Therapeutics, Inc. operates in the biopharmaceutical industry, specializing in the development of immuno-oncology therapies. The company focuses on advancing tumor-activated treatments, including vilastobart (XTX101) and XTX301, which are designed to selectively target cancerous cells while minimizing impact on healthy tissues.
YTD Price Performance: 6.54%
Average Trading Volume: 538,250
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $52.16M
See more insights into XLO stock on TipRanks’ Stock Analysis page.
